PMID- 36607758
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20230111
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 22
IP  - 1
DP  - 2023 Jan 1
TI  - An International Evaluation of a Ceramide-Containing Hydrating Cleanser and 
      Moisturizing Cream for the Improvement of Diabetes Mellitus-Related Xerosis.
PG  - 65-73
LID - 10.36849/JDD.7168 [doi]
AB  - BACKGROUND: Diabetes mellitus (DM) is a common disease. Seventy percent of 
      patients present with a cutaneous complication, including xerosis. 
      Ceramides-containing (CER) skincare promotes a healthy skin barrier. This 
      international, multicenter, open-label cohort study evaluated twice-daily 
      application for 1 month of CER-containing cleanser and moisturizing cream to 
      improve DM-related xerosis. METHODS: Patients between 18 and 75 years with 
      DM-related xerosis at baseline were eligible. Study visits were on days -30 to 0 
      (screening), day 0 (baseline), and week 4 (end of study). Evaluations included 
      the Global Aesthetic Improvement Scale (GAIS) and the physician and 
      subject-scored Dry Skin Classification Scale (DSCS). Subject-scored measures of 
      quality of life (QoL) and satisfaction scale with treatment outcomes and product 
      features took place at the end of the study. Tolerance was assessed by monitoring 
      adverse events (AEs). RESULTS: N = 528 subjects from 19 countries completed 
      treatment, the majority having DM type 2 (82.6%). N = 519 (98.3%) met the primary 
      endpoint criteria (GAIS). The CER-containing skincare regimen resulted in 
      statistically significant improvements from baseline (P<0.001) in all 
      parameters of the physician and subject DSCS scores. Patients reported QoL 
      significantly improved by week 4 (P<0.001). At the end of the study, 99.6% 
      (525) of subjects were satisfied with skincare outcomes and product features 
      (99.4% [524]). No product-related AEs were reported during the study. CONCLUSION: 
      CER-containing cleanser and moisturizer were associated with statistically 
      significant improvements in DM-associated xerosis, physician and subject scored 
      severity, patient satisfaction, and improved QoL. The skincare regimen was well 
      tolerated. J Drugs Dermatol. 2023;22(1):65-73. doi:10.36849/JDD.7168.
FAU - Kirsner, Robert
AU  - Kirsner R
FAU - Andriessen, Anneke
AU  - Andriessen A
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Ceramides)
SB  - IM
MH  - Humans
MH  - *Quality of Life
MH  - Cohort Studies
MH  - Ceramides
MH  - Skin
MH  - Treatment Outcome
MH  - *Diabetes Mellitus
MH  - Skin Cream/therapeutic use
EDAT- 2023/01/07 06:00
MHDA- 2023/01/11 06:00
CRDT- 2023/01/06 12:21
PHST- 2023/01/06 12:21 [entrez]
PHST- 2023/01/07 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
AID - S1545961623P0065X [pii]
AID - 10.36849/JDD.7168 [doi]
PST - ppublish
SO  - J Drugs Dermatol. 2023 Jan 1;22(1):65-73. doi: 10.36849/JDD.7168.